TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

NCT03193853 PHASE2 COMPLETED Results posted

This study evaluates efficacy of TAK- 228 and TAK- 117 followed by cisplatin and nab paclitaxel in patients with metastatic triple negative breast cancer.

Details

Lead sponsor	Joyce O'Shaughnessy
Phase	PHASE2
Status	COMPLETED
Enrolment	12
Start date	Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Dec 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Triple Negative Breast Cancer

Interventions

• Tak-228 & Tak-117
• Cisplatin & Nab Paclitaxel

Countries

United States